Cargando…

Menopause-associated risk of cardiovascular disease

Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a constellation of risk factors, such as visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, non-alcoholic fatty liv...

Descripción completa

Detalles Bibliográficos
Autores principales: Anagnostis, Panagiotis, Lambrinoudaki, Irene, Stevenson, John C, Goulis, Dimitrios G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066596/
https://www.ncbi.nlm.nih.gov/pubmed/35258483
http://dx.doi.org/10.1530/EC-21-0537
_version_ 1784699828095156224
author Anagnostis, Panagiotis
Lambrinoudaki, Irene
Stevenson, John C
Goulis, Dimitrios G
author_facet Anagnostis, Panagiotis
Lambrinoudaki, Irene
Stevenson, John C
Goulis, Dimitrios G
author_sort Anagnostis, Panagiotis
collection PubMed
description Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a constellation of risk factors, such as visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, non-alcoholic fatty liver disease and arterial hypertension. However, an independent association of menopause per se with increased risk of CVD events has only been proven for early menopause (<45 years). Menopausal hormone therapy (MHT) ameliorates most of the CVD risk factors mentioned above. Transdermal estrogens are the preferable regimen, since they do not increase triglyceride concentrations and they are not associated with increased risk of venous thromboembolic events (VTE). Although administration of MHT should be considered on an individual basis, MHT may reduce CVD morbidity and mortality, if commenced during the early postmenopausal period (<60 years or within ten years since the last menstrual period). In women with premature ovarian insufficiency (POI), MHT should be administered at least until the average age of menopause (50–52 years). MHT is contraindicated in women with a history of VTE and is not currently recommended for the sole purpose of CVD prevention. The risk of breast cancer associated with MHT is generally low and is mainly conferred by the progestogen. Micronized progesterone and dydrogesterone are associated with lower risk compared to other progestogens.
format Online
Article
Text
id pubmed-9066596
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-90665962022-05-04 Menopause-associated risk of cardiovascular disease Anagnostis, Panagiotis Lambrinoudaki, Irene Stevenson, John C Goulis, Dimitrios G Endocr Connect Review Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a constellation of risk factors, such as visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, non-alcoholic fatty liver disease and arterial hypertension. However, an independent association of menopause per se with increased risk of CVD events has only been proven for early menopause (<45 years). Menopausal hormone therapy (MHT) ameliorates most of the CVD risk factors mentioned above. Transdermal estrogens are the preferable regimen, since they do not increase triglyceride concentrations and they are not associated with increased risk of venous thromboembolic events (VTE). Although administration of MHT should be considered on an individual basis, MHT may reduce CVD morbidity and mortality, if commenced during the early postmenopausal period (<60 years or within ten years since the last menstrual period). In women with premature ovarian insufficiency (POI), MHT should be administered at least until the average age of menopause (50–52 years). MHT is contraindicated in women with a history of VTE and is not currently recommended for the sole purpose of CVD prevention. The risk of breast cancer associated with MHT is generally low and is mainly conferred by the progestogen. Micronized progesterone and dydrogesterone are associated with lower risk compared to other progestogens. Bioscientifica Ltd 2022-03-08 /pmc/articles/PMC9066596/ /pubmed/35258483 http://dx.doi.org/10.1530/EC-21-0537 Text en © The authors https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Review
Anagnostis, Panagiotis
Lambrinoudaki, Irene
Stevenson, John C
Goulis, Dimitrios G
Menopause-associated risk of cardiovascular disease
title Menopause-associated risk of cardiovascular disease
title_full Menopause-associated risk of cardiovascular disease
title_fullStr Menopause-associated risk of cardiovascular disease
title_full_unstemmed Menopause-associated risk of cardiovascular disease
title_short Menopause-associated risk of cardiovascular disease
title_sort menopause-associated risk of cardiovascular disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066596/
https://www.ncbi.nlm.nih.gov/pubmed/35258483
http://dx.doi.org/10.1530/EC-21-0537
work_keys_str_mv AT anagnostispanagiotis menopauseassociatedriskofcardiovasculardisease
AT lambrinoudakiirene menopauseassociatedriskofcardiovasculardisease
AT stevensonjohnc menopauseassociatedriskofcardiovasculardisease
AT goulisdimitriosg menopauseassociatedriskofcardiovasculardisease